LILRB4-binding antibody and methods of use thereof
AssigneeBoard of Regents, The University of Texas System
InventorsNaveen Sharma, James P. Allison
Life of this patent
Estimating the term…
Abstract
Provided herein are LILRB4-binding antibodies and methods of treating cancer by administering the LILRB4-binding antibodies alone or in combination with other therapies. Recombinant polypeptides comprising the CDRs of LILRB4-binding antibodies are also provided.
Claims20
An isolated monoclonal antibody, wherein the antibody specifically binds to LILRB4 and comprises:
- (I)
- (a) a first VH CDR of SEQ ID NO:
- 1
- (GFMFSSYW);
- (b) a second VH CDR of SEQ ID NO:
- 2
- (INKDVTTT);
- (c) a third VH CDR of SEQ ID NO:
- 3
- (VRNHGSRYAYFDV);
- (d) a first VL CDR of SEQ ID NO:
- 4
- (TQHRTFY);
- (e) a second VL CDR of SEQ ID NO:
- 5
- (VNSDGSQ);
- and
- (f) a third VL CDR of SEQ ID NO:
- 6
- (GVNYESGKQYGYV).
A recombinant polypeptide comprising an antibody VH domain comprising CDRs 1-3 of the VH domain of SEQ ID NOs:
- 1, 2, and 3 and an antibody VL domain comprising CDRs 1-3 of the VL domain of SEQ ID NOs:
- 4, 5, and 6.
A method for treating cancer in a subject comprising administering an effective amount of an antibody that specifically binds to LILRB4 and comprises:
- (I)
- (a) a first VH CDR of SEQ ID NO:
- 1
- (GFMFSSYW);
- (b) a second VH CDR of SEQ ID NO:
- 2
- (INKDVTTT);
- (c) a third VH CDR of SEQ ID NO:
- 3
- (VRNHGSRYAYFDV);
- (d) a first VL CDR of SEQ ID NO:
- 4
- (TQHRTFY);
- (e) a second VL CDR of SEQ ID NO:
- 5
- (VNSDGSQ);
- and
- (f) a third VL CDR of SEQ ID NO:
- 6
- (GVNYESGKQYGYV).
Dependencies are inferred from the claim text.